Alector (ALEC) Cash from Operations (2018 - 2026)
Alector's (ALEC) quarterly Cash from Operations came in at -$34.2 million in Q2 2026, up 30.23% year-over-year from -$26.3 million in Q2 2025, and up 31.31% quarter-over-quarter from -$49.8 million in Q1 2026.
Analysis
Alector (ALEC) Cash from Operations (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Cash from Operations for 9 consecutive years, with -$34.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Operations rose 30.23% year-over-year to -$34.2 million in Q2 2026; TTM through Jun 2026 was -$158.2 million, a 26.61% increase from a year earlier, with the FY2025 full-year figure at -$184.0 million, up 19.95% from the prior year.
- Cash from Operations was -$34.2 million for Q2 2026 at Alector, up from -$49.8 million in the prior quarter.
- Over five years, Cash from Operations peaked at $135.1 million in Q1 2022 and troughed at -$62.8 million in Q2 2024.
- A 5-year average of -$39.0 million and a median of -$49.0 million in 2022 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 356.37% in 2022 and sank 135.94% in 2023, its largest moves.
- Over 5 years, Cash from Operations stood at -$48.9 million in 2022, then rose by 5.84% to -$46.1 million in 2023, then decreased by 19.44% to -$55.0 million in 2024, then advanced by 24.24% to -$41.7 million in 2025, then grew by 17.93% to -$34.2 million in 2026.
- The last three Cash from Operations figures came in at -$34.2 million (Q2 2026), -$49.8 million (Q1 2026), and -$41.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | -34.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.22 Mn |
| Mar 31, 2026 | -49.81 Mn |
| Dec 31, 2025 | -41.69 Mn |
| Sep 30, 2025 | -32.51 Mn |
| Jun 30, 2025 | -49.05 Mn |
| Mar 31, 2025 | -60.78 Mn |
| Dec 31, 2024 | -55.03 Mn |
| Sep 30, 2024 | -50.73 Mn |
| Jun 30, 2024 | -62.80 Mn |
| Mar 31, 2024 | -61.35 Mn |
| Dec 31, 2023 | -46.07 Mn |
| Sep 30, 2023 | -46.54 Mn |
| Jun 30, 2023 | -43.00 Mn |
| Mar 31, 2023 | -48.55 Mn |
| Dec 31, 2022 | -48.93 Mn |
| Sep 30, 2022 | -49.05 Mn |
| Jun 30, 2022 | -57.44 Mn |
| Mar 31, 2022 | 135.09 Mn |
| Dec 31, 2021 | -49.27 Mn |
| Sep 30, 2021 | 445.05 Mn |